Researchers are rapidly focused on retatrutide, a promising drug from Eli Lilly, as a possible advance in body management. Unlike many existing approaches, retatrutide is a twin-action receptor targeting equally GLP-1 and GIP, hormones that affect satiety and blood sugar regulation . Early clinic